EP Patent

EP2526937A1 — Composition for prevention of recurrence of stroke

Assigned to Mochida Pharmaceutical Co Ltd · Expires 2012-11-28 · 13y expired

What this patent protects

Provided is a composition effective for preventing onset and/or recurrence of stroke, in particular, which is expected to be effective for preventing onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular, recurrence o…

USPTO Abstract

Provided is a composition effective for preventing onset and/or recurrence of stroke, in particular, which is expected to be effective for preventing onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular, recurrence of stroke in a patient who is beyond six months after the onset of stroke; i.e., a composition for preventing onset and/or recurrence of stroke, containing ethyl icosapentate as its effective component.

Drugs covered by this patent

Patent Metadata

Patent number
EP2526937A1
Jurisdiction
EP
Classification
—
Expires
2012-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Mochida Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.